Ekong T - Search Results

1

The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study.

Hall LA, McKay SC, Halle-Smith J, Soane J, Osei-Bordom DC, Goodburn L, Magill L, Pinkney T, Radhakrishna G, Valle JW, Corrie P, Roberts KJ; CONTACT Study Group. Hall LA, et al. Br J Cancer. 2023 May;128(10):1922-1932. doi: 10.1038/s41416-023-02220-2. Epub 2023 Mar 23. Br J Cancer. 2023. PMID: 36959376 Free PMC article.

2

Nocturnal haemoglobin oxygen desaturation in urban and rural East African paediatric cohorts with and without sickle cell anaemia: a cross-sectional study.

L'Esperance VS, Ekong T, Cox SE, Makani J, Newton CR, Soka D, Komba A, Kirkham FJ, Hill CM. L'Esperance VS, et al. Among authors: ekong t. Arch Dis Child. 2016 Apr;101(4):352-5. doi: 10.1136/archdischild-2014-306468. Epub 2015 Dec 23. Arch Dis Child. 2016. PMID: 26699539 Free PMC article.

3

Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins.

Jones RG, Ochiai M, Liu Y, Ekong T, Sesardic D. Jones RG, et al. Among authors: ekong t. J Immunol Methods. 2008 Jan 1;329(1-2):92-101. doi: 10.1016/j.jim.2007.09.014. Epub 2007 Oct 23. J Immunol Methods. 2008. PMID: 17976638

4

Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids.

Leung T, Corran PH, Gee C, Ekong TA, Sesardic D. Leung T, et al. Among authors: ekong ta. Dev Biol (Basel). 2002;111:327-32. Dev Biol (Basel). 2002. PMID: 12678257

5

Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro.

Ekong TAN, Feavers IM, Sesardic D. Ekong TAN, et al. Microbiology (Reading). 1997 Oct;143 ( Pt 10):3337-3347. doi: 10.1099/00221287-143-10-3337. Microbiology (Reading). 1997. PMID: 9353935 Free article.

6

Therapeutic botulinum type A toxin: factors affecting potency.

Mclellan K, Das RE, Ekong TA, Sesardic D. Mclellan K, et al. Among authors: ekong ta. Toxicon. 1996 Sep;34(9):975-85. doi: 10.1016/0041-0101(96)00070-0. Toxicon. 1996. PMID: 8896190

7

Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin.

Sesardic D, McLellan K, Ekong TA, Das RG. Sesardic D, et al. Among authors: ekong ta. Pharmacol Toxicol. 1996 May;78(5):283-8. doi: 10.1111/j.1600-0773.1996.tb01376.x. Pharmacol Toxicol. 1996. PMID: 8737961

8

A non-lethal bioassay for potency testing of therapeutic clostridial neurotoxins.

Sesardic D, Ekong T, McLellan KH, Das RG. Sesardic D, et al. Among authors: ekong t. Dev Biol Stand. 1996;86:342. Dev Biol Stand. 1996. PMID: 8785982 No abstract available.

9

Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations.

Ekong TA, McLellan K, Sesardic D. Ekong TA, et al. J Immunol Methods. 1995 Mar 27;180(2):181-91. doi: 10.1016/0022-1759(94)00313-l. J Immunol Methods. 1995. PMID: 7714333

10

Technical influences on immunophenotyping by flow cytometry. The effect of time and temperature of storage on the viability of lymphocyte subsets.

Ekong T, Kupek E, Hill A, Clark C, Davies A, Pinching A. Ekong T, et al. J Immunol Methods. 1993 Sep 15;164(2):263-73. doi: 10.1016/0022-1759(93)90319-3. J Immunol Methods. 1993. PMID: 8370932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters